A federal appeals court on Wednesday revived claims by health plans accusing Takeda Pharmaceuticals of delaying generic versions of its blockbuster diabetes drug Actos by misrepresenting patents it had on the drug.
A unanimous three-judge panel of the 2nd US Circuit Court of Appeals said the health plans had a “highly plausible” theory that Teva Pharmaceutical Industries could have launched generic Actos much earlier than it did if Takeda had described two of its patents in a public listing as covering methods of using Actos, rather than Actos itself.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Withdraws Case Against Microsoft-Activision Merger, Citing Public Interest
May 23, 2025 by
CPI
Charter to Acquire Cox Communications in $35 Billion Deal
May 22, 2025 by
CPI
FTC Targets Media Watchdog Over Alleged Collusion Against Musk’s X
May 22, 2025 by
CPI
FTC Drops Antitrust Case Accusing Pepsi of Squeezing Small Retailers
May 22, 2025 by
CPI
Shein Warns of Higher Costs for French Shoppers Amid EU Fee Proposal
May 22, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros